Press Releases from Charles River
   
 
 
   
   
 

Charles River Announces Third-Quarter 2009 Results

Downloadable version.

  • Sales Decrease 13.1% to $297 Million
  • GAAP Earnings per Share of $0.57 and Non-GAAP Earnings per Share of $0.65
  • Cost-Reduction Initiatives Now Expected to Total $40.0 Million of Savings in 2009
  • Reduces Sales and EPS Guidance for 2009

WILMINGTON, Mass.--(BUSINESS WIRE)--November 3, 2009--Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the third quarter of 2009. For the quarter, net sales were $297.5 million, a decline of 13.1% from $342.2 million in the third quarter of 2008, primarily driven by lower sales in the Preclinical Services (PCS) segment. Foreign currency translation reduced net sales by 1.8%.

On a GAAP basis, net income for the third quarter of 2009 was $37.3 million, or $0.57 per diluted share, compared to net income of $45.5 million, or $0.64 per diluted share, for the third quarter of 2008.

Click here to read the full release.

   
Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
Apr 15 - Putting the 3Rs of Biomedical Rese...
Apr 15 - Charles River Signs Partnership Ag...
Jun 22-Jun 26 - Tucson, AZ - Teratology Society Annual Meeting
May 20-May 22 - San Diego, CA - 2013 American Association of Pharmaceutical Scientists ...
May 23-May 23 - East Lansing, Michigan, USA - The Ins and Outs of Transgenic Colongy Ma...

Charles River Laboratories, Inc.